These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

335 related articles for article (PubMed ID: 28687576)

  • 1. NCCN Guidelines Insights: Antiemesis, Version 2.2017.
    Berger MJ; Ettinger DS; Aston J; Barbour S; Bergsbaken J; Bierman PJ; Brandt D; Dolan DE; Ellis G; Kim EJ; Kirkegaard S; Kloth DD; Lagman R; Lim D; Loprinzi C; Ma CX; Maurer V; Michaud LB; Nabell LM; Noonan K; Roeland E; Rugo HS; Schwartzberg LS; Scullion B; Timoney J; Todaro B; Urba SG; Shead DA; Hughes M
    J Natl Compr Canc Netw; 2017 Jul; 15(7):883-893. PubMed ID: 28687576
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Emerging Role of Olanzapine for Prevention and Treatment of Chemotherapy-Induced Nausea and Vomiting.
    DeRemer DL; Clemmons AB; Orr J; Clark SM; Gandhi AS
    Pharmacotherapy; 2016 Feb; 36(2):218-29. PubMed ID: 26890915
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Medical treatment of chemotherapy-induced nausea and vomiting].
    Herrstedt J
    Ugeskr Laeger; 2007 Feb; 169(9):799-805. PubMed ID: 17355844
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Granisetron in the control of radiotherapy-induced nausea and vomiting: a comparison with other antiemetic therapies.
    Feyer P; Seegenschmiedt MH; Steingraeber M
    Support Care Cancer; 2005 Sep; 13(9):671-8. PubMed ID: 16044252
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antiemesis clinical practice guidelines in oncology.
    Ettinger DS; Bierman PJ; Bradbury B; Ellis G; Ignoffo RJ; Kirkegaard S; Kloth D; Krauss A; Kris MG; Lim D; Markiewicz MA; McNulty R; Noonan K; Stucky-Marshall L; Todaro B; Urba S; Yowell S;
    J Natl Compr Canc Netw; 2004 Sep; 2(5):470-90. PubMed ID: 19780255
    [No Abstract]   [Full Text] [Related]  

  • 6. Overview: oral granisetron (Kytril tablets) prophylaxis for chemotherapy-induced nausea and vomiting.
    Perez EA
    Semin Oncol; 1995 Aug; 22(4 Suppl 10):1-2. PubMed ID: 7570049
    [No Abstract]   [Full Text] [Related]  

  • 7. [Prophylaxis of chemotherapy-induced vomiting and nausea].
    Tóth J; Szántó J
    Magy Onkol; 2008 Dec; 52(4):391-4. PubMed ID: 19068468
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A review of granisetron, 5-hydroxytryptamine3 receptor antagonists, and other antiemetics.
    Hsu ES
    Am J Ther; 2010; 17(5):476-86. PubMed ID: 20844345
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prophylaxis with oral granisetron for acute emesis induced by moderately emetogenic chemotherapy.
    Hesketh P
    Semin Oncol; 1995 Aug; 22(4 Suppl 10):19-23. PubMed ID: 7570050
    [No Abstract]   [Full Text] [Related]  

  • 10. NCCN antiemesis guidelines emphasize 'delayed' emesis, new 5-HT3 inhibitors, and NK-1 blockers.
    National Comprehensive Cancer Network (NCCN)
    J Support Oncol; 2004; 2(4):366. PubMed ID: 15357520
    [No Abstract]   [Full Text] [Related]  

  • 11. First choice for radiation-induced nausea and vomiting--the efficacy and safety of granisetron.
    Goldsmith B
    Acta Oncol; 2004 Sep; 43 Suppl 15():19-22. PubMed ID: 15370626
    [No Abstract]   [Full Text] [Related]  

  • 12. Effect of granisetron on performance status during high-dose interferon therapy.
    Drapkin R; Barolo JL; Blower PR
    Oncology; 1999 Nov; 57(4):303-5. PubMed ID: 10575316
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Slow-release granisetron (APF530) versus palonosetron for chemotherapy-induced nausea/vomiting: analysis by American Society of Clinical Oncology emetogenicity criteria.
    Raftopoulos H; Boccia R; Cooper W; O'Boyle E; Gralla RJ
    Future Oncol; 2015 Sep; 11(18):2541-51. PubMed ID: 26289588
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Chemotherapy-induced emesis and serotonin antagonists].
    Jantunen I; Johansson R
    Duodecim; 1991; 107(14):1112-5. PubMed ID: 1670506
    [No Abstract]   [Full Text] [Related]  

  • 15. 5-Hydroxytryptamine (serotonin) subtype 3 antagonists, a major step in prophylaxis and control of cytostatic and radiation-induced emesis.
    Bremer K
    J Cancer Res Clin Oncol; 1991; 117(1):85-7. PubMed ID: 1997476
    [No Abstract]   [Full Text] [Related]  

  • 16. [Palonosetron in the prevention of chemotherapy-induced nausea and vomiting (CINV) in Italy: pharmacologic, clinical and economic aspects].
    Pradelli L; Eandi M
    Tumori; 2008; 94(2):suppl 26-32. PubMed ID: 18564623
    [No Abstract]   [Full Text] [Related]  

  • 17. Reviewing current and emerging antiemetics for chemotherapy-induced nausea and vomiting prophylaxis.
    Natale JJ
    Hosp Pract (1995); 2015; 43(4):226-34. PubMed ID: 26308912
    [TBL] [Abstract][Full Text] [Related]  

  • 18. NCCN antiemesis practice guidelines.
    Oncology (Williston Park); 1997 Nov; 11(11A):57-89. PubMed ID: 9430179
    [No Abstract]   [Full Text] [Related]  

  • 19. Effective interventions for CINV: NCCN Antiemesis Clinical Practice Guidelines in Oncology.
    ONS News; 2004; 19(9 Suppl):17-8. PubMed ID: 15478570
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transdermal granisetron versus palonosetron for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: a multicenter, randomized, open-label, cross-over, active-controlled, and phase IV study.
    Seol YM; Kim HJ; Choi YJ; Lee EM; Kim YS; Oh SY; Koh SJ; Baek JH; Lee WS; Joo YD; Lee HG; Yun EY; Chung JS
    Support Care Cancer; 2016 Feb; 24(2):945-952. PubMed ID: 26265119
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.